Clinical Trial Results:
The effect of dicloxacillin on oral absorption of drugs
Summary
|
|
EudraCT number |
2021-003814-37 |
Trial protocol |
DK |
Global end of trial date |
21 Jun 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jun 2023
|
First version publication date |
08 Jun 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AKF-400
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05073627 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Southern Denmark
|
||
Sponsor organisation address |
J.B. Winsløws Vej 19, 2nd floor, Odense, Denmark,
|
||
Public contact |
Clinical Pharmacology and Pharmacy, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, +45 65502352 , dbiversen@health.sdu.dk
|
||
Scientific contact |
Clinical Pharmacology and Pharmacy, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, +45 65502352 , dbiversen@health.sdu.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Apr 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
21 Jun 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
21 Jun 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary aim of this study is to investigate if treatment with dicloxacillin can lead to drug-drug interactions through induction of the efflux transporter P-glycoprotein (P-gp).
|
||
Protection of trial subjects |
Trial subjects were asked about adverse events during the trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Nov 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
12
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
We recruited healthy men and women from January 2022 until June 2022. All trial subjects consented to participate in the trial. If in- and exclusion criteria were fulfilled trial subjects were randomized to start in period A or period B. Based on In- and exclusion criteria a medical doctor decided if trial subjects could participate in the trial | ||||||
Pre-assignment
|
|||||||
Screening details |
Trial subjects were screened based on in and exclusion criteria. A medical doctor decided if trial subjects full-filled the criteria and could enter the trial. | ||||||
Period 1
|
|||||||
Period 1 title |
Baseline
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Baseline | ||||||
Arm description |
We measured the baseline level of P-gp without intake of dicloxacillin. All trial subjects worked as their own control. 5 people started in the Baseline period before entering the treatment period, and 5 people started in the treatment period before entering the Baseline period. It has been stated later that 12 people completed the trial. This is not correct. 10 people completed the trial and 2 left due to non-fatal adverse events. Due to an error message, it has not been possible to write this correctly in the boxes below. | ||||||
Arm type |
No administration of drugs | ||||||
Investigational medicinal product name |
Dabigatran etexilate
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule, hard
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
150 mg of dabigatran etexilate was administered to trial subjects after fasting.
|
||||||
|
|||||||
Period 2
|
|||||||
Period 2 title |
Dicloxacillin
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Dicloxacillin | ||||||
Arm description |
Trial subjects ingested dicloxacillin for 30 days. We measured induction of P-gp at 10 days and 28 days. All trial subjects worked as their own control. 5 people started in the Baseline period before entering the treatment period, and 5 people started in the treatment period before entering the Baseline period. It has been stated later that 12 people completed the trial. This is not correct. 10 people completed the trial and 2 left due to non-fatal adverse events. Due to an error message, it has not been possible to write this correctly in the boxes below. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Dicloxacillin
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
During the trial, trial subjects ingested 1 gram dicloxacillin 3 times daily.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline
|
||
Reporting group description |
We measured the baseline level of P-gp without intake of dicloxacillin. All trial subjects worked as their own control. 5 people started in the Baseline period before entering the treatment period, and 5 people started in the treatment period before entering the Baseline period. It has been stated later that 12 people completed the trial. This is not correct. 10 people completed the trial and 2 left due to non-fatal adverse events. Due to an error message, it has not been possible to write this correctly in the boxes below. | ||
Reporting group title |
Dicloxacillin
|
||
Reporting group description |
Trial subjects ingested dicloxacillin for 30 days. We measured induction of P-gp at 10 days and 28 days. All trial subjects worked as their own control. 5 people started in the Baseline period before entering the treatment period, and 5 people started in the treatment period before entering the Baseline period. It has been stated later that 12 people completed the trial. This is not correct. 10 people completed the trial and 2 left due to non-fatal adverse events. Due to an error message, it has not been possible to write this correctly in the boxes below. |
|
|||||||||||||||||||
End point title |
Change in AUC of dabigatran after 28 days of treatment | ||||||||||||||||||
End point description |
Reporting group 1 is the change in AUC between baseline and 10 days of dicloxacillin
Reporting group 2 is the change in AUC between baseline and 28 days of dicloxacillin
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
At baseline and 28 days of dicloxacillin treatment
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Geometric mean ratio | ||||||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
||||||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
||||||||||||||||||
Number of subjects included in analysis |
20
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
equivalence [1] | ||||||||||||||||||
P-value |
> 0.05 | ||||||||||||||||||
Method |
No p-value | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
Notes [1] - We did not calculate p-values, but instead, the confidence interval 95%. If the geometric mean ration contained 1, it was not considered statistically significant. |
|
|||||||||||||||||||
End point title |
Change in Cmax of the dabigatran and dabigatran etexilate | ||||||||||||||||||
End point description |
|||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Comparing data from baseline until day 10 and 28 of dicloxacillin treatment
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Geometric mean ratio | ||||||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
||||||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
||||||||||||||||||
Number of subjects included in analysis |
20
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||
P-value |
> 0.05 [2] | ||||||||||||||||||
Method |
No p-value | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
Notes [2] - We did not calculate the p-value. instead we calculated the 95% confidence interval. If the geometric mean ratio CI 95% contained 1 it was not considered statistical signific |
|
||||||||||||||||
End point title |
Change in T1/2 of the dabigatran and dabigatran etexilate | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Measuring baseline and comparing to 10 and 28 days of dicloxacillin treatment
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Geometric mean ratio | |||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
|||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
|||||||||||||||
Number of subjects included in analysis |
20
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
> 0.05 [3] | |||||||||||||||
Method |
No p-value | |||||||||||||||
Confidence interval |
||||||||||||||||
Notes [3] - We did not calculate the p-value. instead we calculated the 95% confidence interval. If the geometric mean ratio CI 95% contained 1 it was not considered statistical signific |
|
||||||||||||||||
End point title |
Change in formation clearance of the dabigatran | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Measuring baseline and comparing to 10 and 28 days of dicloxacillin treatment
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Geometric mean ratio | |||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
|||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
|||||||||||||||
Number of subjects included in analysis |
20
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
> 0.05 [4] | |||||||||||||||
Method |
No p-value | |||||||||||||||
Confidence interval |
||||||||||||||||
Notes [4] - We did not calculate the p-value. instead we calculated the 95% confidence interval. If the geometric mean ratio CI 95% contained 1 it was not considered statistical signific |
|
||||||||||||||||
End point title |
change in renal clearance of the dabigatran | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Measuring baseline and comparing to 10 and 28 days of flucloxacillin treatment
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Geometric mean ratio | |||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
|||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
|||||||||||||||
Number of subjects included in analysis |
20
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
> 0.05 [5] | |||||||||||||||
Method |
No p-value | |||||||||||||||
Confidence interval |
||||||||||||||||
Notes [5] - We did not calculate the p-value. instead we calculated the 95% confidence interval. If the geometric mean ratio CI 95% contained 1 it was not considered statistical signific |
|
||||||||||||||||
End point title |
Change in Ae (around in urine) of the dabigatran | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Measuring baseline and comparing to 10 and 28 days of dicloxacillin treatment
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Geometric mean ratio | |||||||||||||||
Statistical analysis description |
There were 10 subjects in this analysis as the study was self-controlled
|
|||||||||||||||
Comparison groups |
Baseline v Dicloxacillin
|
|||||||||||||||
Number of subjects included in analysis |
20
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
> 0.05 [6] | |||||||||||||||
Method |
No p-value | |||||||||||||||
Confidence interval |
||||||||||||||||
Notes [6] - We did not calculate the p-value. instead we calculated the 95% confidence interval. If the geometric mean ratio CI 95% contained 1 it was not considered statistical signific |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were were reported from intake of medicine in the trial and 2 weeks after the last dose
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
None | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Ingesting Dicloxacillin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |